Estrella Immunopharma, Inc. (ESLA)
Nasdaq: ESLA · Biological Products, (No Diagnostic Substances) · Emeryville, CA · filing with the SEC since 2021
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Jun 30, 2024 | Jun 30, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Report filed | Mar 18, 2026 | Sep 27, 2024 | · | Mar 14, 2023 | Mar 29, 2022 |
| Research and development | 10,248,545 | 4,108,925 | 10,451,212 | · | · |
| General and administrative | 2,814,129 | 3,201,173 | 663,190 | · | · |
| Total operating expenses | 13,062,674 | 7,310,098 | 11,114,402 | · | · |
| Total costs and expenses | · | · | · | 1,368,219 | 178,992 |
| Operating income | -13,062,674 | -7,310,098 | -11,114,402 | -1,569,527 | -249,146 |
| Interest and investment income | · | · | · | 654,071 | 1,428 |
| Income before income taxes | -13,062,674 | -7,310,098 | -11,114,402 | -915,456 | -247,718 |
| Income tax expense | 838 | 1,625 | · | 80,648 | 0 |
| Net income including non-controlling interests | · | · | · | -996,104 | -247,718 |
| Net income | -13,063,512 | -7,311,723 | -11,114,402 | -996,104 | -247,718 |
| Earnings per share, basic | -0.35 | -0.27 | -36.35 | · | · |
| Earnings per share, diluted | -0.35 | -0.27 | -36.35 | · | · |
| Weighted average shares, basic | 36,820,810 | 27,103,964 | 305,748 | · | 1,179,328 |
| Weighted average shares, diluted | 36,820,810 | 27,103,964 | 305,748 | · | 1,179,328 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:OperatingCostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding